Sunday (23.10.2022)

07:30 – 09:00

Room: Großer Saal

Scientific Session Interactive Case Discussion

  • Tim Illidge
  • Josée Zijlstra

  • Case presentation: Greyzone Lymphoma

    • László Imre Pinczés

  • Case presentation: Anti-PD1 Failure

    • Graham Collins

  • Case presentation: COVID19 immunity in lymphoma

    • Sybille Mellinghoff

  • Case presentation: Primary progressive HL

    • Anne Sophie Jacob

09:15 – 10:15

Room: Großer Saal

Scientific Session Emerging Cellular Therapies – a Role in HL?

  • Stephen Ansell
  • Peter Borchmann
  • 09:15–09:35

    Clinical experience with Cellular Therapy in cH

    • Barbara Savoldo
  • 09:35–09:55

    Design and manufacturing of CD30 CARs for cHL

    • Concetta Quintarelli
  • 09:55–10:15

    Emerging indications for cellular therapy

    • Peter Borchmann

10:30 – 12:00

Room: Großer Saal

Scientific Session Living beyond Lymphoma

  • John Radford
  • Flora van Leeuwen
  • 10:30–10:53

    Towards Lung Cancer Screening in Hodgkin Lymphoma Survivors

    • Kim Linton
  • 10:53–11:16

    GHSG data on fertility, fatigue and social reintegration and the ongoing EMBrACe study

    • Karolin Behringer
  • 11:16–11:21

    WS Report: Living beyond Lymphoma

    • Lena Specht
    • Flora van Leeuwen
  • 11:21–11:34

    Doxorubicin exposure and breast cancer risk in adolescent and adult Hodgkin lymphoma survivors

    • Suzanne Neppelenbroek
  • 11:34–11:47

    Reproduction patterns among Classical Hodgkin Lymphoma Survivors Treated with BEACOPP and ABVD in Sweden, Denmark, and Norway

    • Joshua Entrop
  • 11:47–12:00

    Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study.

    • Michaela Dinan

12:30 – 13:30

Room: Großer Saal

Satellite Symposium (by MSD) Checkpoint Inhibition in Hodgkin Lymphoma – State of the art and future perspectives

  • Peter Borchmann
  • 12:30–12:50

    Firstline therapy of classical Hodgkin Lymphoma – How can immunotherapy improve outcome?

    • Peter Borchmann
  • 12:50–13:10

    The current role of PD-1 inhibition in the treatment of relapsed or refractory classical Hodgkin Lymphoma

    • Bastian von Tresckow
  • 13:10–13:30

    Strategies to enhance checkpoint inhibition

    • Paul J. Bröckelmann

14:00 – 15:30

Room: Großer Saal

Scientific Session Older and Frail Patients

  • Raul Cordoba Mascuñano
  • Andrew Evens
  • 14:00–14:23

    Managing an Older Lymphoma Patient

    • Raul Cordoba Mascuñano
  • 14:23–14:46

    Treatment Strategies in Older HL Patients

    • Andrew Evens
  • 14:46–14:51

    Workshop Report: Innovation for Older patients

    • Paul J. Bröckelmann
    • Alexander Fosså
  • 14:51–15:04

    AVD - a possible golden standard in the first-line treatment of older classical Hodgkin lymphoma patients.

    • Ninja Övergaard
  • 15:04–15:17

    The Effect of Heart Failure on Management and Outcomes of Older Patients with Hodgkin Lymphoma

    • Jenica Upshaw
  • 15:17–15:30

    Treatment patterns and outcomes for Hodgkin's Lymphoma (HL) patients (pts) aged 60 and older: a report from the Brazilian Prospective Hodgkin’s lymphoma Registry

    • Irene Buvat

16:00 – 17:30

Room: Großer Saal

Satellite Symposium (by Takeda) Unraveling Complex Treatment Pathways for Patients with Relapsed / Refractory Hodgkin Lymphoma

  • Anna Sureda
  • 16:00–16:05

    Welcome and introduction

    • Anna Sureda
  • 16:05–16:25

    Navigating Complex Treatment Decisions in R/R HL

    • Theodoros Vasilakopoulos
  • 16:25–16:40

    Challenging Case Study #1

    • Martin Hutchings
  • 16:40–17:00

    Learning from Real-World Evidence to Inform Treatment Decisions in R / R HL

    • Anna Sureda
  • 17:00–17:15

    Challenging Case Study #2

    • Martin Hutchings
  • 17:15–17:30

    Audience Q&A

18:00 – 19:30

Room: Großer Saal

Scientific Session Immunotherapy

  • Philippe Armand
  • Pier Luigi Zinzani
  • 18:00–18:20

    New findings and new challenges since last ISHL

    • Stephen Ansell
  • 18:20–18:33

    Circulating tumor DNA in classical Hodgkin lymphoma patients treated with pembrolizumab and chemotherapy: dynamic response assessment and correlation with baseline total metabolic tumor volume

    • Ryan Lynch
  • 18:33–18:45

    Safety and Dose-Expansion Study of Combination Favezelimab (anti–LAG-3) Plus Pembrolizumab in Anti–PD-1–Naive Patients With Relapsed or Refractory Classical Hodgkin Lymphoma

    • John Timmerman
  • 19:10–19:18

    Vision Corner Stimulus Talk: The future of translational science in HL

    • Christian Steidl
  • 19:18–19:26

    Vision Corner Stimulus Talk: Best use of PD1 blockade in frontline treatment

    • Graham Collins
  • 19:26–19:34

    Vision Corner Stimulus Talk: Leveraging PD1 blockade for cure

    • Paul J. Bröckelmann
  • 19:34–19:55

    Vision Corner: Discussion

    • Paul J. Bröckelmann
    • Graham Collins
    • Christian Steidl

ISHL12 Program at a Glance (PDF)

ISHL12 Program at a Glance (PDF)

ISHL12 Final Program

ISHL12 Final Program